The mission of the Pediatric Oncology Disease Management Group at the Perlmutter Cancer Center is to provide care to children with malignancies that is research-driven, family-centered, and highly personalized.
The group's leadership includes:
- Experienced and nationally prominent pediatric oncologists
- Pediatric neurosurgeons who have national recognition and expertise in pediatric central nervous system (CNS) tumors
- Translational scientists whose research on pediatric malignancies is funded by the National Institutes of Health
Children with malignancies often need treatment from specialists in many different fields of medicine. The group coordinates those specialists into a team approach that is centered on each patient and his or her family.
Research in the Pediatric Oncology Disease Management Group  focuses on translating promising findings from the laboratory to the patient's bedside. There are currently more than 60 open clinical trials for children, adolescents, and young adults with cancer including cooperative and consortia studies, industry-sponsored studies, and investigator-initiated trials. These studies include Phase 0, I, II, and III and pilot therapeutic trials as well as nontherapeutic biology studies covering the full spectrum of pediatric cancers.
Leaders in the Pediatric Oncology Disease Management Group  hold key roles in the Children’s Oncology Group (COG), Neurofibromatosis Consortium, Therapeutic Advances in Childhood Leukemia Consortium (TACL), and the Pediatric Blood and Marrow Transplant Consortium.